We are thrilled to announce our attendance at this week's BIO2024 conference. Taking place on June 3rd in San Diego, this prestigious event promises to bring together top professionals and organizations from the biotechnology and life sciences sectors.

At BIO2024, we look forward to engaging in discussions on partnering opportunities in antibody discovery and engineering, focusing on challenging targets such as GPCR targets, antibodies with unique properties like pH sensitivity and cross-species binding, and novel modalities including BsABs and ADCs.

"I'm excited about the prospect of exchanging ideas and exploring potential collaborations at BIO2024," says Dr. Weian Zhao, CEO of Aureka Biotechnologies, Inc. Dr. Zhao will also present on Aureka Bio's data generation for AI-driven therapeutic design at the "AI Digital Biology Labs Revolution" on June 3rd at UCSD's Guggenheim Theater.

We extend a warm invitation to all attendees to join us at these events, where opportunities for collaboration, knowledge exchange, and networking await.